Tirzepatide
A dual GIP/GLP-1 receptor agonist, combining two incretin pathways in a single molecule for an additive effect on appetite and glucose regulation.
Research status: FDA-approved for type 2 diabetes and weight management.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
Related in Weight Loss